The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Predictors of Prostate Cancer–Specific Mortality After Radical Prostatectomy or Radiation Therapy
Abstract
Purpose: We evaluated predictors of prostate cancer–specific mortality (PCSM) after prostate-specific antigen (PSA) failure after radical prostatectomy (RP) or radiation therapy (RT). Patients and Methods: A total of 1,159 men with clinically localized prostate cancer treated with RP (n = 498) or RT (n = 661) developed PSA failure, and they formed the study cohort. Competing risk regression analyses were used to evaluate whether previously identified predictors of time to metastasis, including post-treatment PSA doubling time (PSA-DT), Gleason score, and interval to PSA failure, could also predict time to PCSM after PSA failure. The cumulative incidence method was used to estimate PCSM after PSA failure. Results: A post-RP PSA-DT of less than 3 months (hazard ratio [HR], 54.9; 95% CI, 16.7 to 180), a post-RT PSA-DT of less than 3 months (HR, 12.8; 95% CI, 7.0 to 23.1), and a biopsy Gleason score of 8 to 10 (HR, 6.1; 95% CI, 3.4 to 10.7) for patients treated with RT were significantly associated with PCSM. Post-RP estimated rates of PCSM 5 years after PSA failure were 31% (95% CI, 17% to 45%) v 1% (95% CI, 0% to 2%) for patients with PSA-DT of less than 3 months v ≥ 3 months. Post-RT estimated rates of PCSM 5 years after PSA failure were 75% (95% CI, 59% to 92%) v 35% (95% CI, 24% to 47%) for patients with a biopsy Gleason score of ≥ 8 v ≤ 7, respectively, and PSA-DT of less than 3 months; these rates were 15% (95% CI, 0.8% to 28%) v 4% (95% CI, 1% to 6%), respectively, for patients with a PSA-DT ≥ 3 months. Conclusion: Patients at high risk for PCSM after PSA failure can be identified based on post-RP PSA-DT or post-RT PSA-DT and biopsy Gleason score. These parameters may be useful in identifying patients for a randomized trial evaluating hormonal therapy with or without docetaxel.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., Oudard, S., Théodore, C., James, N. D., Turesson, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040720 · Cited by 5,735
Cited by
The translational landscape of mTOR signalling steers cancer initiation and metastasis
Hsieh, A. C., Liu, Y., Edlind, M. P., Ingolia, N. T., Janes, M. R., Sher, A., Shi, E. Y., Stumpf, C. R., Christensen, C., Bonham, M. J., et al. (2012) · Nature · doi:10.1038/nature10912 · Cited by 1,313
Stephenson, A. J., Scardino, P. T., Kattan, M. W., Pisansky, T. M., Slawin, K. M., Klein, E. A., Anscher, M. S., Michalski, J. M., Sandler, H. M., Lin, D. W., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.9607 · Cited by 888
Predicting 15-Year Prostate Cancer Specific Mortality After Radical Prostatectomy
Eggener, S. E., Scardino, P. T., Walsh, P. C., Han, M., Partin, A. W., Trock, B. J., Feng, Z., Wood, D. P., Eastham, J. A., Yossepowitch, O., et al. (2011) · Journal of Urology · doi:10.1016/j.juro.2010.10.057 · Cited by 640
Stephenson, A. J., Kattan, M. W., Eastham, J. A., Dotan, Z. A., Bianco, F. J., Lilja, H., & Scardino, P. T. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.0756 · Cited by 529
Van den Broeck, T., van den Bergh, R. C. N., Arfi, N., Gross, T., Moris, L., Briers, E., Cumberbatch, M., De Santis, M., Tilki, D., Fanti, S., et al. (2019) · European Urology · doi:10.1016/j.eururo.2018.10.011 · Cited by 523
Metadata
- Authors
- Zhou, P., Chen, M.-H., McLeod, D., Carroll, P. R., Moul, J. W., & D’Amico, A. V.
- Venue
- Journal of Clinical Oncology
- Published
- 2005-10-01
- Volume
- 23
- Issue
- 28
- Pages
- 6992-6998
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2152715017
- Cited by
- 202
- References
- 2
- FWCI
- 16.52
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Predictors of Prostate Cancer–Specific Mortality After Radical Prostatectomy or Radiation Therapy. https://app.cochat.ai/papers/10.1200/jco.2005.01.2906
- The paper
- Zhou, P., Chen, M.-H., McLeod, D., Carroll, P. R., Moul, J. W., & D’Amico, A. V. (2005). Predictors of Prostate Cancer–Specific Mortality After Radical Prostatectomy or Radiation Therapy. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2005.01.2906
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.